Apellis Pharmaceuticals (APLS) to Release Quarterly Earnings on Thursday

Apellis Pharmaceuticals (NASDAQ:APLS) is scheduled to be announcing its earnings results before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, meeting analysts’ consensus estimates of ($0.54). Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business had revenue of $172.33 million for the quarter, compared to the consensus estimate of $163.37 million. During the same quarter last year, the firm posted ($1.56) EPS. The business’s revenue for the quarter was up 284.3% compared to the same quarter last year. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Apellis Pharmaceuticals Trading Up 2.1 %

Shares of APLS stock traded up $0.81 during mid-day trading on Tuesday, reaching $40.09. The company’s stock had a trading volume of 45,649 shares, compared to its average volume of 1,474,667. The company’s 50 day simple moving average is $39.50 and its 200-day simple moving average is $51.39. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $73.80. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $4.87 billion, a PE ratio of -11.35 and a beta of 0.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on APLS shares. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, May 8th. Robert W. Baird reaffirmed an “outperform” rating and set a $100.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, July 23rd. Citigroup dropped their price target on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. UBS Group dropped their price target on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, The Goldman Sachs Group dropped their price target on shares of Apellis Pharmaceuticals from $90.00 to $77.00 and set a “buy” rating on the stock in a research note on Wednesday, July 17th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.75.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now directly owns 136,998 shares of the company’s stock, valued at approximately $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now directly owns 136,998 shares of the company’s stock, valued at approximately $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Pascal Deschatelets sold 78,907 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the completion of the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $47,261,880.05. The disclosure for this sale can be found here. Company insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).